Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
Howard L. Kaufman, Stephen Marabondo
Publikováno v:
Expert Opinion on Drug Safety. 16:1347-1357
In 1998, high-dose interleukin-2 (IL-2) was the first immunotherapy approved for the treatment of metastatic melanoma based on durable objective responses documented in a subset of patients but widespread utilization was limited by significant toxici
Autor:
James Larkin, Aine O’Reilly
Publikováno v:
Expert Opinion on Drug Safety. 16:955-961
Nivolumab, a human IgG4 monoclonal antibody directed against PD-1, is a checkpoint inhibitor that is licenced in the treatment of metastatic melanoma either as a monotherapy or in combination with ipilimumab, a CTLA-4 inhibitor. The introduction of i
Publikováno v:
Expert Opinion on Drug Safety. :1-9
Multiple myeloma (MM) is the second most common hematologic malignancy and despite significant outcome improvements with novel agents, the majority of patients will eventually relapse and develop treatment resistance. Immunotherapy is emerging as a p
Publikováno v:
Expert Opinion on Drug Safety. :1-17
Invasive fungal diseases (IFDs) are a leading cause of morbidity and mortality among immunocompromised patients with bone marrow failure syndromes, hematological malignancies, hematopoietic stem cell transplantation (HSCT), those admitted in intensiv
Autor:
Oscar Arrieta, Feliciano Barrón, Rosa Luz Luna-Palencia, Andrés F. Cardona, Martha De La Torre-Vallejo
Publikováno v:
Expert Opinion on Drug Safety. 15:1563-1572
Lung cancer tumors present EGFR mutations associated with an increased response rate to tyrosine kinase inhibitors (TKIs). Afatinib acts as an irreversible pan-ErbB-TKI. Areas covered: This review summarizes the results of clinical trials in NSCLC re
Publikováno v:
Expert Opinion on Drug Safety. 15:1421-1426
The introduction of recombinant human erythropoietin revolutionized the management of anemia in patients with chronic kidney disease (CKD). In order to circumvent costly recombinant DNA technology, synthetic chemistry techniques were used to manufact
Publikováno v:
Expert Opinion on Drug Safety. 15:947-954
Pancreatic cancer is a major health burden. Currently, the majority of patients is diagnosed at advanced stages and thus qualifies for palliative chemotherapy. Gemcitabine monotherapy has been the gold standard for many years. Recently, more effectiv